Clinical Trial Update: A Study of M701 (EpCAM and CD3) in Malignant Ascites [Phase 1]

View source ↗

Summary

A Phase 1 study of M701, an EpCAM-CD3 bispecific T-cell engager, in malignant ascites has completed; sponsor is Wuhan YZY Biopharma Co., Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Malignant Ascites

Drugs mentioned

• M701

Snippet

Sponsor: Wuhan YZY Biopharma Co., Ltd. | Conditions: Malignant Ascites, Cancer | Phase 1 | Status: COMPLETED